Back to results
US 2011/0212134 A1Published application
Anti-arthropod vector vaccines, methods of selecting and uses thereof
AssigneeThe Gov't of USA as represented by the Secretary of the Department of Health and Human Services
InventorsJesus G. Valenzuela, Yasmine Belkaid, Shaden Kamhawi, David Sacks, Jose M.C. Ribeiro
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of selecting and uses of anti-arthropod vector vaccines to prevent Leishmaniasis. The present invention also provides compositions for vaccines to prevent Leishmaniasis.
Claims26
1:
- An isolated nucleic acid, encoding a salivary polypeptide of Phlebotomus papatasi.
2:
- The nucleic acid of claim 1, encoding a polypeptide comprising an amino acid sequence set forth as SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:9.
3:
- The nucleic acid of claim 1, encoding a polypeptide comprising an amino acid sequence set forth as SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 or SEQ ID NO:18.
4:
- The nucleic acid of claim 1, wherein the nucleic acid comprises a nucleotide sequence set forth as SEQ ID NO:
- 19, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 or SEQ ID NO:27.
5:
- An isolated salivary polypeptide of Phlebotomus papatasi.
6:
- The isolated polypeptide of claim 5 wherein the polypeptide comprises an N-terminal sequence set forth as SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 or SEQ ID NO:9.
7:
- The isolated polypeptide of claim 5 comprising an amino acid sequence set forth as SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 or SEQ ID NO:18.
8:
- An isolated antigenic or immunogenic fragment of the polypeptide of claim 5.
9:
- The isolated antigenic or immunogenic fragment of claim 8, comprising an amino acid sequence set forth as one of SEQ ID NOS:28-142 or 208-880.
10:
- A nucleic acid that hybridizes under stringent conditions to a nucleic acid having a sequence set forth as one of SEQ ID NOS:19-27.
11:
- The nucleic acid of claim 10, wherein the nucleic acid encodes an antigenic or immunogenic polypeptide.
12:
- A vector comprising the nucleic acid of claim 1.
13:
- The vector of claim 12, wherein the nucleic acid nucleic acid encodes:
- (a)
- SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3,
- SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6,
- SEQ ID NO:
- 7, SEQ ID NO:
- 8
- or
- SEQ ID NO:
- 9;
- (b)
- SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 13,
- SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16,
- SEQ ID NO:
- 17
- or
- SEQ ID NO:
- 18;
- or
- (c)
- SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21,
- SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24,
- SEQ ID NO:
- 25, SEQ ID NO:
- 26
- or
- SEQ ID NO:
- 27.
43 more elements
14:
- A vector comprising the nucleic acid of claim 4.
15:
- A pharmaceutical composition comprising an effective amount of the vector of claim 12 and a pharmaceutically acceptable carrier.
16:
- A pharmaceutical composition comprising an effective amount of the vector of claim 13 and a pharmaceutically acceptable carrier.
17:
- A pharmaceutical composition comprising an effective amount of the vector of claim 14 and a pharmaceutically acceptable carrier.
18:
- A pharmaceutical composition comprising an effective amount of the polypeptide of claim 5 and a pharmaceutically acceptable carrier.
19:
- A pharmaceutical composition comprising an effective amount of the polypeptide of claim 6 and a pharmaceutically acceptable carrier.
20:
- A pharmaceutical composition comprising an effective amount of the polypeptide of claim 7 and a pharmaceutically acceptable carrier.
21:
- A pharmaceutical composition comprising an effective amount of the polypeptide of claim 8 and a pharmaceutically acceptable carrier.
22:
- A pharmaceutical composition comprising an effective amount of the fragment of claim 9 and a pharmaceutically acceptable carrier.
23:
- A method of producing an immune response in a subject, comprising administering to the subject an effective amount of the composition of claim 15 thereby producing an immune response.
24:
- A method of producing an immune response in a subject, comprising administering to the subject an effective amount of the composition of claim 18 thereby producing an immune response.
25:
- A method of preventing Leishmaniasis in a subject, comprising administering to the subject an effective amount of the composition of claim 15, thereby preventing Leishmaniasis.
26:
- A method of preventing Leishmaniasis in a subject, comprising administering to the subject an effective amount of the composition of claim 18 thereby preventing Leishmaniasis.